Efficacy of Xanomeline on Cognitive Dysfunction

October 16, 2025

Done Poster Aaic 2025 Toronto Xanomeline Cognitive Dysfunction V2 New Logo

Download PDF

Psychotropic drug abuse, particularly involving amphetamines and ketamine, has been shown to induce alterations in dopaminergic innervation, neuronal structure, and cognitive function. For AAIC 2025, WuXi Biology showcased a poster on a study that investigated whether xanomeline, an M1/M4 muscarinic receptor agonist, could ameliorate cognitive dysfunction induced by amphetamine and ketamine abuse.

Drugs that increase hyperlocomotion (scopolamine, ketamine, amphetamine) often impair novel object recognition (NOR) performance in rodents. In this study, the authors demonstrate that xanomeline enhanced object recognition memory in a rat cognitive impairment model, suggesting that muscarinic receptor agonists may hold therapeutic potential for treating cognitive impairments associated with psychotropic drug abuse.

Discuss Program

Discuss Your Program with Us

Share your development goals and key challenges with our experts to define the right path forward.

Discuss Your Program